Lazertinib
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
Oct 16, 2019 → Nov 14, 2022
NCT ID
NCT04075396About Lazertinib
Lazertinib is a phase 1/2 stage product being developed by Yuhan for Carcinoma, Non-Small-Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT04075396. Target conditions include Carcinoma, Non-Small-Cell Lung.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non-Small-Cell Lung were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05716672 | Pre-clinical | UNKNOWN |
| NCT05338619 | Phase 2 | UNKNOWN |
| NCT04075396 | Phase 1/2 | Completed |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung